NASDAQ Small-Caps in Focus: SNYR, RXT, CDIO, HTLM, KOS — Value Plays Gaining Momentum Getting your Trinity Audio player ready... As investors search for “top NASDAQ growth stocks 2026,” “small-cap breakout stocks,” and “functional beverage market growth,” several emerging names are gai...

NASDAQ Small-Caps in Focus: #SNYR, #RXT, #CDIO, #HTLM, #KOS — Value Plays Gaining Momentum

thestreetreports.com/nasdaq-small...

Breaking News: ( NASDAQ: #CDIO ) BioMedNewsBreaks - Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Schedules Investor Conference Call for Feb. 19, 2026

JUST IN: ( NASDAQ: #CDIO ) US Companies Moving the Markets, Morning edition <br>Thu, Feb 19, 2026 as of 10.00 am ET

Most searched small-cap stocks, Wed Jan 7th - #INVX #RXRX #BITF #BBAI #CLSK #LAC #CDIO #UWMC #RR #GLUE #VTYX #MNTS #HOUS #UAMY #ERAS #DNN #CRML #RZLV #NVVE #PLUG - More: crystalequityresearch.com/most-searche... - #smallcap

Cardio Diagnostics, Aimil Ltd. and Dr. Lal PathLabs Limited Partner to Launch the PrecisionCHD™ Test in India Cardio Diagnostics (NASDAQ: CDIO) announced a strategic agreement with Aimil and Dr. Lal PathLabs to launch the PrecisionCHD™ blood test in India. This marks Cardio Diagnostics’ first expansion outside the United States and targets earlier detection and personalized management of coronary heart disease (CHD).PrecisionCHD combines epigenetics, genetics and AI to detect obstructive and non‑obstructive CHD, including INOCA and MINOCA; supporting data were presented at the American Heart Association Scientific Sessions. Initial integration into Dr. Lal PathLabs’ network (290+ labs, 300+ MD pathologists) has begun, with commercial rollout expected in 2026.

#CDIO Cardio Diagnostics, Aimil Ltd. and Dr. Lal PathLabs Limited Partner to Launch the PrecisionCHD™ Test in India

www.stocktitan.net/news/CDIO/cardio-diagnos...

Cardio Diagnostics Holdings, Inc. and Southdale YMCA Announce New Heart Health Partnership to Serve the Edina, Minnesota Community Cardio Diagnostics (Nasdaq: CDIO) announced a community partnership with the Southdale YMCA in Edina, Minnesota to expand heart health education and AI‑powered cardiovascular testing.Key details: the Southdale YMCA serves ~14,000 members (about 80% adults). Cardio Diagnostics will host an in‑person education session on January 26, 2026 at 11:30 AM CT and participate in the Southdale YMCA Heart Health Fair on February 25, 2026, 8 AM–4 PM CT. Discounted clinician‑ordered tests Epi+Gen CHD (three‑year CHD risk) and PrecisionCHD will be available via telemedicine, at‑home kits, or onsite blood collection.

#CDIO Cardio Diagnostics Holdings, Inc. and Southdale YMCA Announce New Heart Health Partnership to Serve the Edina, Minnesota Community

www.stocktitan.net/news/CDIO/cardio-diagnos...

Cardio Diagnostics Receives Final Gapfill Payment Rates for AI-Driven Cardiovascular Tests from the Centers for Medicare and Medicaid Services (CMS) Cardio Diagnostics Holdings, Inc., an AI-powered precision cardiovascular medicine company, today announced that the Centers for Medicare and Medicaid Services has issued a final gapfill payment rate of $854 for both the Epi+ Gen CHD™ and PrecisionCHD™ tests. This finalized rate represents an increase from the preliminary gapfill payment rates of $350 for...

#CDIO Cardio Diagnostics Receives Final Gapfill Payment Rates for AI-Driven Cardiovascular Tests from the Centers for Medicare and Medicaid Services (CMS)

www.stocktitan.net/news/CDIO/cardio-diagnos...

Cardio Diagnostics Holdings, Inc. and YMCA of East Tennessee Partner to Bring Heart Health Education and Advanced Testing to East Tennessee Community Cardio Diagnostics (Nasdaq: CDIO) is partnering with YMCA of East Tennessee to offer heart‑health education and discounted AI‑powered cardiovascular tests to the Knoxville area.Programs begin in November 2025 with six "Wisdom Wednesdays" sessions at Tennova and Davis branches; a community Heart Health Fair and on‑site sample collection are planned for February 2026 (American Heart Month). Tests available at a discounted rate include Epi+Gen CHD (3‑year CHD risk) and PrecisionCHD (diagnosis/management); both are physician‑ordered, epigenetics and AI‑based blood tests with at‑home or event collection via a telemedicine platform.The program targets YMCA’s >40,000 members and the wider East Tennessee community amid elevated state cardiovascular mortality (state: 22.9% of deaths; national: 20.1%).

#CDIO Cardio Diagnostics Holdings, Inc. and YMCA of East Tennessee Partner to Bring Heart Health Education and Advanced Testing to East Tennessee Community

www.stocktitan.net/news/CDIO/cardio-diagnos...

Cardio Diagnostics Holdings, Inc. Expands Provider Network, Adding 15 New Provider Organizations From Across the United States Cardio Diagnostics (Nasdaq: CDIO) announced it added 15 new provider organizations across the United States on October 21, 2025, expanding adoption of its AI-driven tests Epi+Gen CHD™ and PrecisionCHD™. The new partners span four regions (Northeast, South, Midwest, West) and a range of care models including concierge, functional, longevity, direct primary care, and primary care practices.By integrating the company's combined epigenetic-genetic and AI testing, providers aim to obtain actionable insights into coronary heart disease and heart attack risk to guide personalized prevention and management.

#CDIO Cardio Diagnostics Holdings, Inc. Expands Provider Network, Adding 15 New Provider Organizations From Across the United States

www.stocktitan.net/news/CDIO/cardio-diagnos...

Henkel befördert Frank Tenbrock zum CDIO Frank Tenbrock folgt auf Michael Nilles als Digital- und IT-Chef bei Henkel. Er kommt aus den eigenen Reihen.

Frank Tenbrock folgt auf Michael Nilles als Digital- und IT-Chef bei Henkel. Er kommt aus den eigenen Reihen. #henkel #cio #cdio #daxkonzern #itmanager

Cardio Diagnostics Receives Gapfill Payment Rates for AI-Driven Cardiovascular Tests from the Centers for Medicare and Medicaid Services (CMS) Cardio Diagnostics (NASDAQ:CDIO) has received preliminary gapfill payment rates from CMS for its AI-powered cardiovascular tests. The rates are set at $350 for Epi+Gen CHD™ and $684.76 for PrecisionCHD™, effective January 1, 2025.Both tests received dedicated CPT PLA codes earlier in 2024. PrecisionCHD™ aids in CHD diagnosis through genetic and epigenetic marker analysis, while Epi+Gen CHD™ assesses three-year risk for CHD events. The tests are performed via blood draw, offering non-invasive cardiovascular assessment for Medicare beneficiaries.These preliminary rates represent a significant milestone in expanding Medicare access to advanced cardiovascular testing, particularly important as heart disease remains the leading cause of death in the US, with over 700,000 American deaths in 2022.

#CDIO Cardio Diagnostics Receives Gapfill Payment Rates for AI-Driven Cardiovascular Tests from the Centers for Medicare and Medicaid Services (CMS)

www.stocktitan.net/news/CDIO/cardio-diagnos...

Revolutionary AI Blood Test Could Transform Heart Disease Treatment: Cardio Diagnostics Launches Major Clinical Study New clinical study combines AI-powered blood test with FDA-approved anti-inflammatory drug to revolutionize coronary heart disease treatment. See breakthrough approach.

#CDIO Cardio Diagnostics Enters Into an Agreement with AGEPHA Pharma to Advance Precision Assessment and Management of Inflammation Associated with Coronary Heart Disease

www.stocktitan.net/news/CDIO/cardio-diagnos...

Cardio Diagnostics Secures Japanese Patent for AI-Driven Cardiovascular Disease Detection Technology Cardio Diagnostics (NASDAQ: CDIO) has secured a new Japanese patent (No. 7672192) for its AI-powered cardiovascular disease detection technology. The patent, titled 'Compositions and Methods for Detecting Predisposition to Cardiovascular Disease,' is exclusively licensed from the University of Iowa Research Foundation and was invented by CEO Meesha Dogan and CMO Robert Philibert. This addition strengthens CDIO's global intellectual property portfolio, which already includes patents in the US, Europe, Australia, India, and China. The technology combines epigenetic and genetic biomarkers with machine learning algorithms to detect cardiovascular disease risk and presence, representing a significant advancement in early detection and prevention of heart disease in international markets.

#CDIO Cardio Diagnostics Secures Japanese Patent for AI-Driven Cardiovascular Disease Detection Technology

www.stocktitan.net/news/CDIO/cardio-diagnos...

Cardio Diagnostics Broadens Access to Precision Cardiovascular Care with New Practice Partnerships Across U.S. Mainland and Puerto Rico Cardio Diagnostics (Nasdaq: CDIO) has announced a significant expansion of its healthcare practice partnerships across the United States and Puerto Rico. The company has added 10 new practices across five states and Puerto Rico, integrating its AI-powered cardiovascular blood tests - Epi+Gen CHD™ and PrecisionCHD™.The new partnerships span various healthcare models, including concierge, direct primary care, functional, and integrative medicine practices. Notable expansions include practices in the Midwest (Indiana and Ohio), Southern California, Arizona, and the company's first partner in Puerto Rico. The tests combine genetic predisposition analysis with lifestyle-influenced epigenetic changes to provide early detection and risk assessment for heart disease.This expansion represents a significant step toward preventive cardiology, as these practices aim to shift from reactive to preventive care models. The partnerships particularly focus on independent practices committed to modernizing patient experience and early heart disease detection.

#CDIO Cardio Diagnostics Broadens Access to Precision Cardiovascular Care with New Practice Partnerships Across U.S. Mainland and Puerto Rico

www.stocktitan.net/news/CDIO/cardio-diagnos...

Just In: ( NASDAQ: #CDIO ) CDIO announced stock split 1-30

Cardio Diagnostics Holdings, Inc. Announces 1-for-30 Reverse Stock Split Cardio Diagnostics Holdings (NASDAQ: CDIO) has announced a 1-for-30 reverse stock split effective May 13, 2025. The split aims to regain compliance with Nasdaq Capital Market's minimum bid price requirement. Following the split, CDIO's outstanding shares will decrease from approximately 52 million to 1.7 million, while authorized shares remain at 300 million.The reverse split was authorized by stockholders on November 15, 2024, and approved by the Board on April 10, 2025. No fractional shares will be issued, with shares being rounded to the nearest whole number. The company's warrants, stock options, and shares under the 2022 Equity Incentive Plan will be proportionally adjusted to reflect the split ratio.

#CDIO Cardio Diagnostics Holdings, Inc. Announces 1-for-30 Reverse Stock Split

www.stocktitan.net/news/CDIO/cardio-diagnos...

AI-Powered Heart Disease Testing Breakthrough: Cardio Diagnostics Signs 7 Strategic Healthcare Alliances Cardio Diagnostics partners with leading healthcare providers across 6 states to deliver AI-driven cardiovascular testing, expanding access to precision heart disease detection.

#CDIO Cardio Diagnostics Expands the Reach of its AI-Driven Precision Cardiovascular Medicine Tests by Partnering with Seven New Provider Organizations

www.stocktitan.net/news/CDIO/cardio-diagnos...

Cardio Diagnostics Secures Medicare Coverage Path for AI-Powered Heart Disease Tests Cardio Diagnostics achieves key milestone as CMS approves pricing framework for its AI-driven cardiovascular tests, setting stage for Medicare coverage starting 2025.

#CDIO Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests

www.stocktitan.net/news/CDIO/cardio-diagnos...

Thoughts on #APVO #CDIO #CADL this morning 📈 #stocks #stockmarket #stockstowatch #stocktips #news

What is a Chief Digital Information Officer? S3E06 Shuri Network Podcast · Episode

Hi! I co-host the official Shuri Network podcast w/ my co-host @carolynbarkin.bsky.social. We're now in series 3, and our latest release is with @andycallow.bsky.social who talks to us about his take on the role of a #CDIO Listen here or wherever you get your pods👇 open.spotify.com/episode/6pr0...

What is a Chief Digital Information Officer? S3E06 Shuri Network Podcast · Episode

It's #podcast Tuesday @ The Shuri Network podcast & the 1st one I've posted about here!

@ayesharahim.bsky.social and I talk to @andycallow.bsky.social about being a #CDIO #leadership and #allyship. I loved chatting with Andy, hope you enjoy it as well.

open.spotify.com/episode/6pr0...

Here for all things #digitalhealth #digitaltransformation #digitalnurse #CNIO #CCIO #CDIO #CXIO #digitalinnovation #digitalresearch especially in the NHS. With a side of clincial research, cats, and diabetes humour #datasavelives

JUST IN: ( NASDAQ: #CDIO ) Expected US Company Earnings on Monday, November 11th, 2024

#StockMarket #News

Spotlight: Healthcare and Tech VTAK, ORGO, CDIO, LAZR, VLCN - Cardio Diagnostics Hldgs (NASDAQ:CDIO), Organogenesis Hldgs (NASDAQ:ORGO) This week, several companies are under the spotlight due to specific developments. This feature will offer an in-depth look at five such companies.&nbsp; On May 13, Catheter Precision Inc. (NYSE:VTAK)...

Spotlight: Healthcare and Tech
#VTAK, #ORGO, #CDIO, #LAZR, #VLCN
www.benzinga.com/pressrelease...